Johnson & Johnson Explores $20 Billion Sale of DePuy Synthes Orthopedics Unit
核心洞察
Johnson & Johnson is preparing a potential sale of its orthopedics unit DePuy Synthes, which could be valued at more than $20 billion according to sources familiar with the matter.
The company acquired DePuy Synthes for $21.3 billion in 2011 and announced plans in October 2025 to separate the orthopedics business within 18 to 24 months.
Several large private equity firms are considering joint bids for the unit, which generates $9.3 billion in annual sales from hip and knee replacement devices.
Johnson & Johnson is preparing a potential sale of its orthopedics unit DePuy Synthes, with the business potentially valued at more than $20 billion as major buyout firms circle the opportunity, according to people familiar with the matter.
The healthcare giant is assembling documents and financials for DePuy Synthes ahead of meetings with possible buyers in the coming weeks. Several large private equity firms are considering teaming up to potentially acquire the unit, which produces hip and knee replacement devices and generated $9.3 billion in annual sales.
Strategic Separation Plans
In October 2025, Johnson & Johnson announced plans to separate its orthopedics business to enhance strategic and operational focus, targeting completion within 18 to 24 months. At the time, CFO Joseph Wolk indicated the company hadn't yet decided how to enact the split but was preparing for the possibility of a spinoff, describing it as "the most time-consuming and resource-intensive approach."
Wolk stated that Johnson & Johnson was "open to ideas that others might have," including a sale or another transaction if it resulted in greater value for shareholders.
Valuation and Market Interest
Bloomberg Intelligence (搜索) estimates the unit could be worth approximately $20 billion, or $28 billion including debt. The potential sale represents a significant development for a business that Johnson & Johnson acquired for $21.3 billion in 2011.
Bank of America (搜索) analysts noted that "the exit makes sense, in our view; in the long-term, DePuy Synthes should benefit from improved focus and become more competitive."
Buyer Interest and Market Dynamics
Beyond private equity interest, DePuy Synthes may also attract attention from strategic medical device players given its market position in orthopedic implants. However, discussions remain preliminary, and a transaction is not assured.
The potential divestiture comes as Johnson & Johnson reported strong fourth-quarter 2025 results, with adjusted earnings of $2.46 per share, up 20.6% year over year and beating consensus estimates of $2.44. The company expects 2026 sales of $99.50 billion to $100.5 billion, compared to consensus estimates of $98.89 billion.
Johnson & Johnson shares closed up 0.78% at $246.91 following the earnings report, reflecting investor confidence in the company's strategic direction and financial performance.